The approval of Aβ-clearing antibodies like Leqembi (lecanemab) and Kisunla (donanemab) marked a landmark shift toward disease-modifying therapies in Alzheimer’s,…
HOME > BUSINESS
BUSINESS
- Samsung, Biogen Idec Agree to Set Up Biosimilar Joint Venture Company
December 7, 2011
- Ethical Drug Sales Up 7% in October; 6th Monthly Increase in a Row: Crecon
December 7, 2011
- AnGes MG Reaches Agreement with Japanese, Korean Companies to Develop Therapeutic CIN Vaccine
December 6, 2011
- US Sunovion to Resubmit NDA for Antiepileptic Treatment STEDESA
December 6, 2011
- Toray to Accelerate Pharmaceutical Business, Targeting ¥40 Billion in Sales
December 6, 2011
- US Consulting Firm Says New Forecast Will Be Necessary for Anticancer Drug Market
December 6, 2011
- Taiho to Cooperate in Doctor-Led Clinical Trial
December 6, 2011
- Takeda Sets Up Global Vaccine Business Company to Enhance Global Operations
December 6, 2011
- OncoTherapy Confirms Safety of Cancer Vaccine OCV-105 in PI Trial
December 6, 2011
- Eisai’s US Research Subsidiary Starts Full Operation
December 5, 2011
- Pfizer, MSD Issue Repeated Warnings for Improper Use of Pneumococcal Vaccines Prevnar, Pneumovax
December 5, 2011
- Teijin Pharma Gets Good Response for Feburic from Medical Institutions: President Arao
December 2, 2011
- Pfizer President Umeda Says Steady Performance for Lyrica, “Business Objectives Achieved”
December 2, 2011
- Bayer, Regeneron Initiate PIII Trial for VEGF Trap-Eye in China
December 2, 2011
- Takeda Announces Overflow of Contaminated Water at Shonan Research Center
December 2, 2011
- Nippon Shinyaku to Open Representative Office in Beijing
December 2, 2011
- DSP, Yoshitomiyakuhin to Terminate Copromotion Agreement for Antipsychotics Lonasen, Lullan
December 2, 2011
- Confusion Seen Temporarily Over FDA Approval for Lipitor Generic
December 2, 2011
- Generic Drug Makers to Continue Launching Generics of Major Drugs Even with 60% Rule
December 2, 2011
- Teva Receives Tentative Approval for Generic Lipitor in the US
December 2, 2011
ページ
PHARMA JAPAN welcomes JETRO New York’s Shunsuke Tani as a guest columnist. In occasional contributions, Tani will share his perspectives on US pharmaceutical policy, industry developments, and life in America, drawing on his firsthand experience in the US.---Hello from New…
Japan should fundamentally overhaul its cost-effectiveness assessment (CEA) scheme while putting a hold on CEA-based price adjustments, a new ruling…
Japanese Prime Minister Sanae Takaichi said on October 14 that the government will consider the necessary measures for the FY2027…
Eli Lilly’s breast cancer drug Imulrio (imlunestrant) is finally joining Japan’s NHI price list on October 14, nearly 300 days…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…